Latest News and Press Releases

Data from Phase 2 study of HB-200 in combination with pembrolizumab in head and neck cancers expected in 2Q 2023 Phase 1 HB-300 trial in metastatic castration-resistant prostate cancer open for...

NEW YORK and VIENNA, Austria, Feb. 13, 2023 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapies based on its proprietary arenavirus...

Roche to receive license for HOOKIPA’s HB-700 program and option to license a second undisclosed novel arenaviral immunotherapyHOOKIPA to receive $25 million in upfront cash as well as potential...

Alternating 2-vector therapy showed superior antigen-specific T cell responses, more robust anti-tumor activity and similar tolerability vs. single-vector therapyPhase 2 to proceed with alternating...

Oral and poster presentations highlight robust and high-quality immune responses following administration of novel arenaviral therapeutic vaccines in preclinical setting Alternating 2-vector...

Phase 1 data show single-vector HB-201 and 2-vector HB-202/HB-201 were generally well tolerated, rapidly induced tumor-specific T cells and showed anti-tumor activity in heavily pre-treated head and...

Preclinical data on combination with co-stimulatory 4-1BB agonists or adoptive T cell transfer showed potent T cell responses and significant tumor controlPreclinical data also expand evidence on...

Lead oncology candidate HB-200 demonstrated high antigen-specific T cell responses and encouraging anti-tumor activity in heavily pre-treated head and neck cancer patientsHOOKIPA received FDA Fast...